Pharmacogenetics refers to genetic differences in metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects. Pharmacogenetics is generally regarded as the study or clinical testing of genetic variation that gives rise to differing responses to drugs, while pharmacogenomics is the broader application of genomic technologies to new drug discovery and further characterization of older drugs.
Making Genetics has the experience and necessary knowledge for the development of pharmacogenetic and pharmacogenomic analysis, especially those related to oncology and neurological/psychiatric diseases, including different sequencing techniques, pyrosequencing,...
Our extensive experience in molecular biology techniques and bioinformatics enable us to study and develop proposals for analysis in other areas (cardiology, dermatology...), providing, as an active principal, a pre-test counseling and bioinformatic tools.
In this sense, one of the key points for the pharmacogenetics progress involves the proper use and/or improvement of bioinformatic tools. Thus Making Genetics will assess the functional significance of rare variants with potential pharmacogenetic impact, contributing to data interpretation and subsequent steps to be followed.
The clinical value of these tests may be difficult to interpret, so guidelines that link the result of a pharmacogenetic test with therapeutic recommendations is wise. This implies the continuous updating of clinical guidelines for treatment, a task in which Making Genetics can provide expertise and knowledge.
Making Genetics offers pharmacogenetic and pharmacogenomic services.